HR 5811 · 115th Congress · Health
Long-Term Opioid Efficacy Act of 2018
Bill Progress
✓
Introduced✓
Committee✓
House Vote4
Senate5
EnactedLatest: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.(2018-06-20)
Plain Language Summary
[AI summary unavailable — showing source text]
Long-Term Opioid Efficacy Act of 2018 This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).…
Summarized by Claude AI · Non-partisan · For informational purposes only
CBO Cost Estimate
Congressional Budget OfficeH.R. 5811, a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements for certain controlled substances, and for other purposes
Jun 11, 2018As ordered reported by the House Committee on Energy and Commerce on May 17, 2018
Full CBO report ↗Official non-partisan budget analysis by the Congressional Budget Office
Cosponsors (3)
3 Republicans